Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/4/2018 |
| Start Date: | February 24, 2015 |
| End Date: | September 2019 |
| Contact: | Sasan Karimi, MD |
| Phone: | 212-639-8633 |
Evaluation of Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion
The purpose of this study is to assess imaging methods including Dynamic Contrast Enhanced
Magnetic Resonance Imaging (DCE-MRI) and perfusion for the cancer that has spread to the
spine. The study aims to see if using these methods will help better see response to
treatment with radiation in patients with spine metastases from any solid cancer.
Magnetic Resonance Imaging (DCE-MRI) and perfusion for the cancer that has spread to the
spine. The study aims to see if using these methods will help better see response to
treatment with radiation in patients with spine metastases from any solid cancer.
Inclusion Criteria:
- Adult patients 18 years of age or older
- Known pathological diagnosis of any solid cancer.
- Metastatic spinal lesions 1 cm or greater in diameter.
- Patients who are already eligible for and are to be treated with hypofractionated or
single dose radiation for their spinal lesions.
Note: The patients must have their treatments at MSKCC.
Exclusion Criteria:
- Patients with renal failure or history of allergic reaction to Gadavist will be
excluded.
- Patients who would be normally excluded from undergoing an MRI examination as per
Memorial Hospital for Cancer and Allied Disease Screening Questionnaire for MRI.
- Patients with a pacemaker, aneurysm clip or any other condition that would warrant
avoidance of a strong magnetic field.
- Patients with inability to cooperate for an MRI exam due to claustrophobia or high
levels of anxiety.
- Female patients who are pregnant or nursing.
- Patients with eGFR < 30 are not eligible to higher risk of NSF.
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-8633
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
